M8W Stock Overview
A biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
MediWound Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.80 |
| 52 Week High | US$20.40 |
| 52 Week Low | US$7.30 |
| Beta | 0.84 |
| 11 Month Change | 0.64% |
| 3 Month Change | -4.82% |
| 1 Year Change | 105.19% |
| 33 Year Change | 0.77% |
| 5 Year Change | -13.19% |
| Change since IPO | -74.15% |
Recent News & Updates
Recent updates
Shareholder Returns
| M8W | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 6.0% | -1.2% | -0.02% |
| 1Y | 105.2% | -20.1% | 8.2% |
Return vs Industry: M8W exceeded the German Pharmaceuticals industry which returned -22% over the past year.
Return vs Market: M8W exceeded the German Market which returned 7.4% over the past year.
Price Volatility
| M8W volatility | |
|---|---|
| M8W Average Weekly Movement | 8.8% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: M8W's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: M8W's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 100 | Ofer Gonen | www.mediwound.com |
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma.
MediWound Ltd. Fundamentals Summary
| M8W fundamental statistics | |
|---|---|
| Market cap | €173.66m |
| Earnings (TTM) | -€19.18m |
| Revenue (TTM) | €19.34m |
8.8x
P/S Ratio-8.9x
P/E RatioIs M8W overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| M8W income statement (TTM) | |
|---|---|
| Revenue | US$20.14m |
| Cost of Revenue | US$17.47m |
| Gross Profit | US$2.67m |
| Other Expenses | US$22.64m |
| Earnings | -US$19.97m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 26, 2024
| Earnings per share (EPS) | -1.85 |
| Gross Margin | 13.25% |
| Net Profit Margin | -99.17% |
| Debt/Equity Ratio | 0% |
How did M8W perform over the long term?
See historical performance and comparison